{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:47:51Z","timestamp":1767980871074,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T00:00:00Z","timestamp":1469232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Precision Biologics Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00280-016-3108-5","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T08:42:29Z","timestamp":1469263349000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer"],"prefix":"10.1007","volume":"78","author":[{"given":"Muhammad S.","family":"Beg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilofer S.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Torrealba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Mavroukakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melony A.","family":"Beatson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Arlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,23]]},"reference":[{"issue":"1","key":"3108_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5\u201329. doi: 10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3108_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00010.2005","volume":"86","author":"MC Rose","year":"2006","unstructured":"Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 86(1):245\u2013278. doi: 10.1152\/physrev.00010.2005","journal-title":"Physiol Rev"},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"934757","DOI":"10.1155\/2011\/934757","volume":"2011","author":"J Luka","year":"2011","unstructured":"Luka J, Arlen PM, Bristol A (2011) Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. J Biomed Biotechnol 2011:934757. doi: 10.1155\/2011\/934757","journal-title":"J Biomed Biotechnol"},{"issue":"5","key":"3108_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19980302)75:5<767::AID-IJC17>3.0.CO;2-3","volume":"75","author":"J Bara","year":"1998","unstructured":"Bara J, Chastre E, Mahiou J, Singh RL, Forgue-Lafitte ME, Hollande E, Godeau F (1998) Gastric M1 mucin, an early oncofetal marker of colon carcinogenesis, is encoded by the MUC5AC gene. Int J Cancer 75(5):767\u2013773. doi: 10.1002\/(SICI)1097-0215(19980302)75:5<767:AID-IJC17>3.0.CO;2-3","journal-title":"Int J Cancer"},{"issue":"2","key":"3108_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ijc.2910470222","volume":"47","author":"J Bara","year":"1991","unstructured":"Bara J, Gautier R, Mouradian P, Decaens C, Daher N (1991) Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 47(2):304\u2013310","journal-title":"Int J Cancer"},{"key":"3108_CR6","first-page":"D1256","volume":"6","author":"C Bolos de","year":"2001","unstructured":"de Bolos C, Real FX, Lopez-Ferrer A (2001) Regulation of mucin and glycoconjugate expression: from normal epithelium to gastric tumors. Front Biosci 6:D1256\u2013D1263","journal-title":"Front Biosci"},{"key":"3108_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-230X-6-4","volume":"6","author":"B Kocer","year":"2006","unstructured":"Kocer B, McKolanis J, Soran A (2006) Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol 6:4. doi: 10.1186\/1471-230X-6-4","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3108_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<210::AID-IJC9>3.0.CO;2-U","volume":"80","author":"AE Bartman","year":"1999","unstructured":"Bartman AE, Sanderson SJ, Ewing SL, Niehans GA, Wiehr CL, Evans MK, Ho SB (1999) Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps. Int J Cancer 80(2):210\u2013218. doi: 10.1002\/(SICI)1097-0215(19990118)80:2<210:AID-IJC9>3.0.CO;2-U","journal-title":"Int J Cancer"},{"issue":"1","key":"3108_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1309\/9R66-73QE-C06D-86Y4","volume":"122","author":"SK Lau","year":"2004","unstructured":"Lau SK, Weiss LM, Chu PG (2004) Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122(1):61\u201369. doi: 10.1309\/9R66-73QE-C06D-86Y4","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"3108_CR10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/1097-0142(19850801)56:3<480::AID-CNCR2820560312>3.0.CO;2-2","volume":"56","author":"A Hollinshead","year":"1985","unstructured":"Hollinshead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J (1985) Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer 56(3):480\u2013489","journal-title":"Cancer"},{"issue":"6","key":"3108_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00262-013-1420-z","volume":"62","author":"SP Patel","year":"2013","unstructured":"Patel SP, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA (2013) Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother 62(6):1011\u20131019. doi: 10.1007\/s00262-013-1420-z","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3108_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026S0959-8049(08)00873-3","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi: 10.1016\/j.ejca.2008.10.026S0959-8049(08)00873-3","journal-title":"Eur J Cancer"},{"issue":"15","key":"3108_CR13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89(15):1138\u20131147","journal-title":"J Natl Cancer Inst"},{"key":"3108_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-LB-161","author":"SP Patel","year":"2013","unstructured":"Patel SP, Morse MA, Diaz LA, Azad NS, Haley S, Arlen PM (2013) A phase I safety study of NPC-1C, a novel, therapeutic antibody to treat pancreas and colorectal cancers. Cancer Res. doi: 10.1158\/1538-7445.AM2013-LB-161","journal-title":"Cancer Res"},{"key":"3108_CR15","unstructured":"Bristol AKJ, Luka J, Stafford L, Gupta R, Arlen P (2011) Pre-clinical studies of a novel antibody to treat pancreatic and colorectal tumors (abstract). In: Proceedings of the 102nd annual meeting of the American association for cancer research, p 4584"},{"issue":"20","key":"3108_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, Group RS (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919. doi: 10.1056\/NEJMoa1414325","journal-title":"N Engl J Med"},{"issue":"5","key":"3108_CR17","first-page":"324","volume":"10","author":"A Grothey","year":"2012","unstructured":"Grothey A (2012) Regorafenib in metastatic colorectal cancer. Clin Adv Hematol Oncol 10(5):324\u2013325","journal-title":"Clin Adv Hematol Oncol"},{"issue":"19","key":"3108_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. doi: 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"9863","key":"3108_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312. doi: 10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"issue":"18","key":"3108_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. doi: 10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3108-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3108-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:04:04Z","timestamp":1498331044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3108-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3108-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,23]]}}}